Anacor Pharmaceuticals Inc. (ANAC: Quote) announced that its board has appointed Paul Berns, Anacor's Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Berns succeeds David Perry who has served as Anacor's President and Chief Executive Officer since 2002.
Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies.
Anacor said that Berns has served as a member of the company's board since 2012. From March 2006 to August 2012, Berns served as President and Chief Executive Officer, and member of the Board of Directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in August 2012.
From June 2002 to July 2005, Berns was president, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll and, from 1990 to 2000, Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Berns has been a director of Jazz Pharmaceuticals, PLC since 2010 and of XenoPort, Inc. since 2005.
| || |
| To receive FREE breaking news email alerts for Anacor Pharmaceuticals, Inc. and others in your portfolio|
by RTT Staff Writer
For comments and feedback: email@example.com